SCHEMBL113602

SCHEMBL113602

CON=Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SRC P12931 3/20 0.50
PLA2G7 Q13093 1/20 0.48
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
FAAH O00519 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
NOX1 Q9Y5S8 1/20 0.41
TRPA1 O75762 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10797604 1.00 LMNA (0.52) LMNAL3MBTL1SRCPLA2G7PPARG
SCHEMBL113601 1.00 LMNA (0.52) LMNAL3MBTL1SRCPLA2G7PPARG
SCHEMBL13397720 0.87 SRC (0.61) LMNASRCPPARGPPARANPC1
SCHEMBL14572074 0.87 SRC (0.48) LMNAL3MBTL1SRCPLA2G7PPARG
SCHEMBL28173018 0.87 SRC (0.48) LMNAL3MBTL1SRCPLA2G7PPARG
SCHEMBL14572076 0.83 NPC1 (0.55) LMNAL3MBTL1SRCPPARGPPARA
Propane SCHEMBL11032480 0.82 PPARG (0.41) LMNAL3MBTL1SRCPLA2G7PPARG
Propene SCHEMBL11100982 0.82 SRC (0.41) LMNAL3MBTL1SRCPLA2G7PPARG
SCHEMBL2901541 0.81 LMNA (0.48) LMNAL3MBTL1PLA2G7NPC1RAB9A
SCHEMBL28484755 0.81 LMNA (0.48) LMNAL3MBTL1PLA2G7NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 795 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3624849-A1 COMBINATION THERAPY USING ASCOCHLORIN DERIVATIVE Hoshino, Tatsuo (JP) 2020-03-25 EP claimed
WO-2018212363-A1 COMBINATION THERAPY USING ASCOCHLORIN DERIVATIVE NRL PHARMA, INC. (JP) 2018-11-22 WO claimed
US-9371262-B2 One-step intermolecular electrocyclic rearrangement process GIVAUDAN S.A. (CH) 2016-06-21 US claimed
CN-103467300-B A kind of synthetic method of o-nitrobenzaldehyde compounds JIANG University OF TECHNOLOGY (CN) 2016-02-24 CN claimed
US-20140288326-A1 NOVEL PROCESS GIVAUDAN S.A. (CH) 2014-09-25 US claimed
CN-103889969-A Novel process GIVAUDAN SA 2014-06-25 CN claimed
CN-103467300-A Synthesizing method for o-nitrobenzaldehyde compound UNIV ZHEJIANG TECHNOLOGY 2013-12-25 CN claimed
WO-2013060011-A1 NOVEL PROCESS GIVAUDAN SA (CH) 2013-05-02 WO claimed
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US claimed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US claimed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US claimed
EP-1737823-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP claimed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO claimed
US-20050113450-A1 Antibacterial agents PHARMACIA & UPJOHN COMPANY 2005-05-26 US claimed
US-20040142981-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-07-22 US claimed
WO-2004018414-A2 ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
WO-2004018461-A2 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
WO-2004018428-A1 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
CN-1349416-A Contraceptive compositions contaiing indoline derivatives and progestational agents AMERICAN HOME PROD (US) 2002-05-15 CN claimed
EP-0030702-B1 PROPIONIC-ACID ESTERS, PREPARATION OF THESE COMPOUNDS, HERBICIDES CONTAINING THEM AS ACTIVE INGREDIENTS, USE OF SUCH COMPOUNDS AND AGENTS AS HERBICIDES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1983-08-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113450-A1 Antibacterial agents CLPP, SPOUT1, SAMHD1 LMNA 4552/4885L3MBTL1 3559/4885SRC 3829/4885
US-20140288326-A1 NOVEL PROCESS COASY, ADH1C, AKR1C2 LMNA 517/4885L3MBTL1 3962/4885SRC 4546/4885
US-20040142981-A1 Antibacterial benzoic acid derivatives GABRD, PHB1, GABBR1 LMNA 4062/4885L3MBTL1 2013/4885SRC 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.